Novartis Fast Tracks MS Drug with European and U.S. Authorities

GALWAY, IRELAND--October 23, 2018--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss pharmaceutical giant Novartis International AG (NYSE:NVS) (Basel, Switzerland) is aiming to exploit the largely untouched multiple sclerosis (MS) market by filing for European and U.S. approval for the Siponimod drug for secondary progressive multiple sclerosis (SPMS).

Within this article: Details new MS drug filings, impact for patients, existing Novartis MS drugs and financial worth, recent job cuts announcement